Coagulation Disorders in Patients With Cirrhosis
Publication Date: September 24, 2021
Key Points
Key Points
- Significant alterations in laboratory parameters — such as platelet count (PLT) and prothrombin time/international normalized ratio (PT/INR) — routinely accompany cirrhosis.
- However, the risks of both bleeding and thrombosis are not accurately quantitated by standard testing in this population.
- The best strategies to identify patients at risk for bleeding or thrombosis, to provide appropriate prophylaxis in patients at risk for clinically significant bleeding, to screen for and treat portal vein thrombosis, and to prevent clinically significant thromboembolic events are currently unknown.
Diagnosis
...gnosis
Testing Strategy
...tic Testing (VET)In patients with stable cirrh...
...patients with stable cirrhosis (wit...
Portal Vein Thrombosis (PVT)...
...s with cirrhosis, the AGA suggests aga...
Treatment
...reatmen...
...dure Prophylaxis...
...and/or Fresh Frozen Plasma (FFP)In patients...
...tin receptor agonist (TPO-Ras)In patients with...
...mboembolism (VTE) Prophylaxis With Anticoagulati...
...italized patients with cirrhosis and who o...
...ute Non-tumoral Portal Vein Thrombosis...
...nts with cirrhosis and acute or subacute...
...ial Fibrillat...
...tients with cirrhosis and atrial fibrillation...
Table 1. Procedure Risk Stratificat...